Zhejiang Medicine approves 2025 restricted stock incentive plan recipients

Zhejiang Medicine Co., Ltd. announced that its board of directors’ remuneration and assessment committee has completed verification of the incentive recipients for the 2025 Restricted Stock Incentive Plan. This follows a public disclosure period from October 28, 2025, to November 6, 2025, during which the company did not receive any objections.

The committee confirmed that all individuals on the proposed incentive list meet the qualifications outlined in relevant company and national regulations. The beneficiaries include directors, senior management, and core backbone employees, excluding independent directors, shareholders holding 5% or more of the company’s shares, and their related parties.

The verification process involved reviewing employment contracts, identification documents, and job descriptions. The committee concluded that the listed individuals’ eligibility to participate in the incentive plan is lawful and effective.